Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials
D Hagins, C Orkin, E S Daar, A Mills, C Brinson, E DeJesus, F A Post, J Morales-Ramirez, M Thompson, O Osiyemi, B Rashbaum, H-J Stellbrink, C Martorell, H Liu, Y-P Liu, D Porter, S E Collins, D SenGupta, M Das, D Hagins, C Orkin, E S Daar, A Mills, C Brinson, E DeJesus, F A Post, J Morales-Ramirez, M Thompson, O Osiyemi, B Rashbaum, H-J Stellbrink, C Martorell, H Liu, Y-P Liu, D Porter, S E Collins, D SenGupta, M Das
Abstract
Objectives: The single-tablet regimen rilpivirine, emtricitabine and tenofovir alafenamide (RPV/FTC/TAF) for treatment of HIV-1-infected adults was approved based on bioequivalence. We assessed the clinical efficacy, safety and tolerability of switching to RPV/FTC/TAF from either RPV/FTC/tenofovir disoproxil fumarate (TDF) or efavirenz (EFV)/FTC/TDF.
Methods: We conducted two distinct randomized, double-blind, active-controlled, noninferiority trials in participants taking RPV/FTC/TDF (Study 1216) and EFV/FTC/TDF (Study 1160). Each study randomized virologically suppressed (HIV-1 RNA < 50 copies/mL) adults (1:1) to switch to RPV/FTC/TAF or continue their current regimen for 96 weeks. We evaluated efficacy as the proportion with HIV-1 RNA < 50 copies/mL using the Food and Drug Administration snapshot algorithm and prespecified bone and renal endpoints at week 96.
Results: We randomized and treated 630 participants in Study 1216 (RPV/FTC/TAF, n = 316; RPV/FTC/TDF, n = 314) and 875 in Study 1160 (RPV/FTC/TAF, n = 438; EFV/FTC/TDF, n = 437). In both studies, the efficacy of switching to RPV/FTC/TAF was noninferior to that of continuing baseline therapy at week 96, with respective percentages of patients with HIV RNA < 50 copies/mL being 89.2% versus 88.5% in Study 1216 [difference 0.7%; 95% confidence interval (CI) -4.3 to +5.8%] and 85.2% versus 85.1% in Study 1160 (difference 0%; 95% CI -4.8 to +4.8%). No participant on RPV/FTC/TAF developed treatment-emergent resistance versus two on EFV/FTC/TDF and one on RPV/FTC/TDF. Compared with continuing baseline therapy, significant improvements in bone mineral density and renal tubular markers were observed in the RPV/FTC/TAF groups (P < 0.001).
Conclusions: Switching to RPV/FTC/TAF from RPV/FTC/TDF or EFV/FTC/TDF was safe and effective and improved bone mineral density and renal biomarkers up to 96 weeks with no cases of treatment-emergent resistance.
Keywords: HIV; bone mineral density; renal disease; rilpivirine; tenofovir alafenamide.
© 2018 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.
Figures
References
- Mollan KR, Smurzynski M, Eron JJ et al Association between efavirenz as initial therapy for HIV‐1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med 2014; 161: 1–10.
- Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J Antimicrob Chemother 2009; 64: 910–928.
- Shubber Z, Calmy A, Andrieux‐Meyer I et al Adverse events associated with nevirapine and efavirenz‐based first‐line antiretroviral therapy: a systematic review and meta‐analysis. AIDS 2013; 27: 1403–1412.
- Arribas JR, Thompson M, Sax PE et al Brief report: randomized, double‐blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV‐1 treatment: week 144 results. J Acquir Immune Defic Syndr 2017; 75: 211–218.
- Raffi F, Orkin C, Clarke A et al Brief report: long‐term (96‐Week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV‐infected, virologically suppressed adults. J Acquir Immune Defic Syndr 2017; 75: 226–231.
- Society EAC . European AIDS Clinical Society (EACS) Guidelines Version 9.0. 2017: 102.
- The Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents . Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Available at: . (accessed 17 October 2017).
- DeJesus E, Ramgopal M, Crofoot G et al Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV‐1 infection: a randomised, double‐blind, multicentre, phase 3b, non‐inferiority study. Lancet HIV 2017; 4: e205–e213.
- Orkin C, DeJesus E, Ramgopal M et al Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV‐1 infection: a randomised, double‐blind, multicentre, phase 3b, non‐inferiority study. Lancet HIV 2017; 4: e195–e204.
- Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41.
- U S Department of Health and Human Services FaDAF, Center for Drug Evaluation and Research (CDER) . Human immunodeficiency virus‐1 infection: developing antiretroviral drugs for treatment. Guidance for Industry. November, 2015.
- Sax PE, Wohl D, Yin MT et al Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV‐1 infection: two randomised, double‐blind, phase 3, non‐inferiority trials. Lancet 2015; 385: 2606–2615.
- Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir‐associated kidney toxicity in HIV‐infected patients: a review of the evidence. Am J Kidney Dis 2011; 57: 773–780.
- Gutierrez F, Fulladosa X, Barril G, Domingo P. Renal tubular transporter‐mediated interactions of HIV drugs: implications for patient management. AIDS Rev 2014; 16: 199–212.
- Behrens G, Maserati R, Rieger A et al Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV‐infected adults with raised cholesterol: effect on lipid profiles. Antivir Ther 2012; 17: 1011–1020.
- Mulligan K, Glidden DV, Anderson PL et al Decreases in cholesterol in HIV‐seronegative men using emtricitabine/tenofovir pre‐exposure prophylaxis: lipid results of iPrEx [Abstract 005]. 15th International Workshop on Co‐morbidities and Adverse Drug Reactions in HIV Brussels, Belgium, 2013.
- Santos JR, Saumoy M, Curran A et al The lipid‐lowering effect of tenofovir/emtricitabine: a randomized, crossover, double‐blind, placebo‐controlled trial. Clin Infect Dis 2015; 61: 403–408.
- Tungsiripat M, Kitch D, Glesby MJ et al A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS 2010; 24: 1781–1784.
- Goff DC Jr, Lloyd‐Jones DM, Bennett G et al 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: S49–S73.
- Friis‐Moller N, Ryom L, Smith C et al An updated prediction model of the global risk of cardiovascular disease in HIV‐positive persons: the Data‐collection on Adverse Effects of Anti‐HIV Drugs (D:A:D) study. Eur J Prev Cardiol 2016; 23: 214–223.
- Huhn G, Rijnders B, Thompson M et al Switching from TDF to TAF in Patients with High Risk for CKD [Presentation]. Boston, MA, ASM Microbe, 2016.
- SUSTIVA® and Bristol‐Myers Squibb Company . SUSTIVA® (efavirenz) capsules and tablets for oral use. US Prescribing Information. Princeton, NJ: Revised January, 2017.
- Thamrongwonglert P, Chetchotisakd P, Anunnatsiri S, Mootsikapun P. Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV‐infected patients with dyslipidemia. HIV Clin Trials 2016; 17: 12–16.
- Ford N, Shubber Z, Pozniak A et al Comparative safety and neuropsychiatric adverse events associated with efavirenz use in first‐line antiretroviral therapy: a systematic review and meta‐analysis of randomized trials. J Acquir Immune Defic Syndr 2015; 69: 422–429.
- Lochet P, Peyriere H, Lotthe A, Mauboussin JM, Delmas B, Reynes J. Long‐term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med 2003; 4: 62–66.
Source: PubMed